bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Prevention of Colorectal Carcinogenesis by DNA-Binding Small-Molecule Curaxin CBL0137 Involves Suppression of Wnt Signaling
Authors: Kirsanov Kirill , Fetisov Timur , Lesovaya Ekaterina A. , Maksimova Varvara , Trukhanova Lubov , Antoshina Elena , Gor'kova Tatiana , Morozova Olga , Safina Alfiya , Fleyshman Daria , Salimov Ramiz , Shipaeva Elena , Ivanov Roman , Leonov Andrey , Purmal Andrei A. , Belitsky Gennady A. , Gudkov Andrei V. , Gurova Katerina V. , Yakubovskaya Marianna G.
Published: April 2023

Abstract
Chemoprevention is considered a valid approach to reduce the incidence of colorectal cancer, one of the most common malignancies worldwide. Here, we investigated the tumor-preventive activity of curaxin CBL0137. This compound represents a new class of nonmutagenic DNA-binding small molecules that alter chromatin stability and inhibit the function of the histone chaperone FACT. Among downstream effects of CBL0137 treatment are activation of p53 and type I interferons and inhibition of NFκB, HSF1, and MYC. In addition, our data show that in both human and mouse colorectal cancer cells in vitro, CBL0137 inhibits the APC/WNT/β-catenin signaling pathway, which plays a key role in colon carcinogenesis. Using quantitative RT-PCR and microarray hybridization, we have demonstrated decreased expression of multiple components and downstream targets of the WNT pathway in colon cancer cells treated with CBL0137. At the same time, CBL0137 induced expression of WNT antagonists. Inhibition of WNT signaling activity by CBL0137 was also confirmed by luciferase reporter assay. Tumor-preventive activity of CBL0137 in vivo was tested in a murine model of colorectal carcinogenesis induced by 1,2-dimethylhydrazine (DMH), which is known to involve WNT pathway dysregulation. After DMH subcutaneous treatment, mice were administered CBL0137 in drinking water. Efficacy of CBL0137 in suppressing development of colorectal cancer in this model was evidenced by reduced incidence of adenocarcinomas and adenomas in both males and females and decrease in tumor multiplicity. These data support the prospective use of CBL0137 in chemoprevention of colorectal cancer as well as of other malignances associated with activated WNT signaling.
Data from Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study
Authors: Agorastos Theodoros , Chatzistamatiou Kimon , Tsertanidou Athena , Mouchtaropoulou Evangelia , Pasentsis Konstantinos , Kitsou Anastasia , Moysiadis Theodoros , Moschaki Viktoria , Skenderi Alkmini , Katsiki Evangelia , Aggelidou Stamatia , Venizelos Ioannis , Ntoula Maria , Daponte Alexandros , Vanakara Polyxeni , Garas Antonios , Stefos Theodoros , Vrekoussis Thomas , Lymberis Vasilis , Kontomanolis Emmanuel N. , Makrigiannakis Antonis , Manidakis George , Deligeoroglou Efthimios , Panoskaltsis Theodoros , Decavalas George O. , Michail George , Kalogiannidis Ioannis , Koukoulis George , Zempili Paraskevi , Halatsi Despina , Truva Theoni , Piha Vaia , Agelena Georgia , Chronopoulou Athanasia , Vaitsi Violetta , Chatzaki Ekaterini , Paschopoulos Minas , Adonakis George , Kaufmann Andreas M. , Hadzidimitriou Anastasia , Stamatopoulos Kostas
Published: April 2023

Abstract
Self-sampling for human papillomavirus (HPV) testing is an alternative to physician sampling particularly for cervical cancer screening nonattenders. The GRECOSELF study is a nationwide observational cross-sectional study aiming to suggest a way to implement HPV-DNA testing in conjunction with self-sampling for cervical cancer screening in Greece, utilizing a midwifery network. Women residing in remote areas of Greece were approached by midwives, of a nationwide network, and were provided with a self-collection kit (dry swab) for cervicovaginal sampling and asked to answer a questionnaire about their cervical cancer screening history. Each sample was tested for high-risk (hr) HPV with the Cobas HPV test. HrHPV-Positive women were referred to undergo colposcopy and, if needed, treatment according to colposcopy/biopsy results. Between May 2016 and November 2018, 13,111 women were recruited. Of these, 12,787 women gave valid answers in the study questionnaire and had valid HPV-DNA results; hrHPV prevalence was 8.3%; high-grade cervical/vaginal disease or cancer prevalence was 0.6%. HrHPV positivity rate decreased with age from 20.7% for women aged 25–29 years to 5.1% for women aged 50–60 years. Positive predictive value for hrHPV testing and for HPV16/18 genotyping ranged from 5.0% to 11.6% and from 11.8% to 27.0%, respectively, in different age groups. Compliance to colposcopy referral rate ranged from 68.6% (for women 25–29) to 76.3% (for women 40–49). For women residing in remote areas of Greece, the detection of hrHPV DNA with the Cobas HPV test, on self-collected cervicovaginal samples using dry cotton swabs, which are provided by visiting midwives, is a promising method for cervical cancer secondary prevention.
Data from Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population
Authors: Duarte-Salles Talita , Misra Sandeep , Stepien Magdalena , Plymoth Amelie , Muller David , Overvad Kim , Olsen Anja , Tjønneland Anne , Baglietto Laura , Severi Gianluca , Boutron-Ruault Marie-Christine , Turzanski-Fortner Renee , Kaaks Rudolf , Boeing Heiner , Aleksandrova Krasimira , Trichopoulou Antonia , Lagiou Pagona , Bamia Christina , Pala Valeria , Palli Domenico , Mattiello Amalia , Tumino Rosario , Naccarati Alessio , Bueno-de-Mesquita H.B(as). , Peeters Petra H. , Weiderpass Elisabete , Quirós J. Ramón , Agudo Antonio , Sánchez-Cantalejo Emilio , Ardanaz Eva , Gavrila Diana , Dorronsoro Miren , Werner Mårten , Hemmingsson Oskar , Ohlsson Bodil , Sjöberg Klas , Wareham Nicholas J. , Khaw Kay-Tee , Bradbury Kathryn E. , Gunter Marc J. , Cross Amanda J. , Riboli Elio , Jenab Mazda , Hainaut Pierre , Beretta Laura
Published: April 2023

Abstract
We previously identified osteopontin (OPN) as a promising marker for the early detection of hepatocellular carcinoma (HCC). In this study, we investigated the association between prediagnostic circulating OPN levels and HCC incidence in a large population-based cohort. A nested case–control study was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each case was matched to two controls and OPN levels were measured in baseline plasma samples. Viral hepatitis, liver function, and α-fetoprotein (AFP) tests were also conducted. Conditional logistic regression models were used to calculate multivariable odds ratio (OR) and 95% confidence intervals (95% CI) for OPN levels in relation to HCC. Receiver operating characteristics curves were constructed to determine the discriminatory accuracy of OPN alone or in combination with other liver biomarkers in the prediction of HCC. OPN levels were positively associated with HCC risk (per 10% increment, ORmultivariable = 1.30; 95% CI, 1.14–1.48). The association was stronger among cases diagnosed within 2 years of follow-up. Adding liver function tests to OPN improved the discriminatory performance for subjects who developed HCC (AUC = 0.86). For cases diagnosed within 2 years, the combination of OPN and AFP was best able to predict HCC risk (AUC = 0.88). The best predictive model for HCC in this low-risk population is OPN in combination with liver function tests. Within 2 years of diagnosis, the combination of OPN and AFP best predicted HCC development, suggesting that measuring OPN and AFP could identify high-risk groups independently of a liver disease diagnosis. Cancer Prev Res; 9(9); 758–65. ©2016 AACR.
Data from Mitotic Spindle Apparatus Abnormalities in Chronic Obstructive Pulmonary Disease Cells: A Potential Pathway to Lung Cancer
Authors: Thaiparambil Jose , Dong Lingyun , Jasso Diana , Huang Jian-An , El-Zein Randa A.
Published: April 2023

Abstract
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease characterized by irreversible lung damage resulting in airflow limitation, abnormal permanent air-space enlargement, and emphysema. Cigarette smoking is the major cause of COPD with 15% to 30% of smokers developing either disease. About 50% to 80% of patients with lung cancer have preexisting COPD and smokers who have COPD are at an increased risk for developing lung cancer. Therefore, COPD is considered an independent risk for lung cancer, even after adjusting for smoking. A crucial early event in carcinogenesis is the induction of the genomic instability through alterations in the mitotic spindle apparatus. To date, the underlying mechanism by which COPD contributes to lung cancer risk is unclear. We hypothesized that tobacco smoke carcinogens induce mitotic spindle apparatus abnormalities and alter expression of crucial genes leading to increased genomic instability and ultimately tumorigenesis. To test our hypothesis, we assessed the genotoxic effects of a potent tobacco-smoke carcinogen [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, (NNK)] on bronchial epithelial cells from patients with COPD and normal bronchial epithelial cells and identified genes associated with mitotic spindle defects and chromosome missegregation that also overlap with lung cancer. Our results indicate that exposure to NNK leads to a significantly altered spindle orientation, centrosome amplification, and chromosome misalignment in COPD cells as compared with normal epithelial cells. In addition, we identified several genes (such as AURKA, AURKB, and MAD2L2) that were upregulated and overlap with lung cancer suggesting a potential common pathway in the transition from COPD to lung cancer.
Data from DNA Hypomethylation Contributes to Genomic Instability and Intestinal Cancer Initiation
Authors: Sheaffer Karyn L. , Elliott Ellen N. , Kaestner Klaus H.
Published: April 2023

Abstract
Intestinal cancer is a heterogeneous disease driven by genetic mutations and epigenetic changes. Approximately 80% of sporadic colorectal cancers are initiated by mutation and inactivation of the adenomatous polyposis coli (APC) gene, which results in unrestrained intestinal epithelial growth and formation of adenomas. Aberrant DNA methylation promotes cancer progression by the inactivation of tumor suppressor genes via promoter methylation. In addition, global DNA hypomethylation is often seen before the formation of adenomas, suggesting that it contributes to neoplastic transformation. Previous studies employed mice with a hypomorphic mutation in DNA methyltransferase 1 (Dnmt1), which exhibited constitutive global DNA hypomethylation and decreased tumorigenesis in the ApcMin/+ mouse model of intestinal cancer. However, the consequences of intestinal epithelial-specific acute hypomethylation during ApcMin/+ tumor initiation have not been reported. Using temporally controlled intestinal epithelial-specific gene ablation, we show that total loss of Dnmt1 in the ApcMin/+ mouse model of intestinal cancer causes accelerated adenoma initiation. Deletion of Dnmt1 precipitates an acute response characterized by hypomethylation of repetitive elements and genomic instability, which surprisingly is followed by remethylation with time. Two months post-Dnmt1 ablation, mice display increased macroadenoma load, consistent with a role for Dnmt1 and DNA methylation in maintaining genomic stability. These data suggest that DNA hypomethylation plays a previously unappreciated role in intestinal adenoma initiation. Cancer Prev Res; 9(7); 534–46. ©2016 AACR.

See related article by Lee and Laird, p. 509
Data from Cancer-related Beliefs and Preventive Health Practices among Residents of Rural versus Urban Counties in Alabama
Authors: Aly Salma , Daniel Casey L. , Bae Sejong , Scarinci Isabel C. , Hardy Claudia M. , Fouad Mona N. , Baskin Monica L. , Hoenemeyer Teri , Acemgil Aras , Demark-Wahnefried Wendy
Published: April 2023

Abstract
Higher prevalence of cancer-related risk factors, for example, tobacco use, obesity, poor diet, and physical inactivity, is observed in the U.S. Deep South and likely contributes to its increased cancer burden. While this region is largely rural, it is unknown whether cancer-related beliefs and lifestyle practices differ by rural–urban status or are more influenced by other factors. We contacted 5,633 Alabamians to complete a cross-sectional survey to discern cancer-related beliefs and lifestyle practices, and compared data from respondents residing in rural- versus urban-designated counties. Findings were summarized using descriptive statistics; rural–urban subgroups were compared using two-tailed, χ2 and t tests. Multivariable logistic regression models were used to explore associations by rural–urban status and other sociodemographic factors. Surveys were completed by 671 rural- and 183 urban-county respondents (15.2% response rate). Overall, the prevalence for overweight and obesity (77.8%) and sugar-sweetened beverage intake (273–364 calories/day) was higher than national levels. Most respondents (58%) endorsed raising the state tobacco tax. Respondents from rural- versus urban-designated counties were significantly more likely to be racial/ethnic minority, have lower education, employment, income, food security, and internet access, and endorse fatalistic cancer-related beliefs (<0.05; although regression models suggested that cancer belief differences are more strongly associated with education than counties of residence). Lifestyle practices were similar among rural–urban subgroups. Few rural–urban differences in cancer-related beliefs and lifestyle practices were found among survey respondents, although the high overall prevalence of fatalistic health beliefs and suboptimal lifestyle behaviors suggests a need for statewide cancer prevention campaigns and policies, including increased tobacco taxation.

Prevention Relevance: Cancer incidence and mortality are higher in the U.S. Deep South, likely due to increased tobacco-use, obesity, poor diet, and physical inactivity. This study explores whether cancer-related beliefs and lifestyle practices differ by rural-urban status or other sociodemographic factors in a random sample of 855 residents across Alabama.
Data from A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia
Authors: Kuriakose Moni Abraham , Ramdas Kunnambath , Dey Bindu , Iyer Subramanya , Rajan Gunaseelan , Elango Kalavathy K. , Suresh Amritha , Ravindran Divya , Kumar Rajneesh R. , R Prathiba , Ramachandran Surya , Kumar Nisha Asok , Thomas Gigi , Somanathan Thara , Ravindran Hiran K. , Ranganathan Kannan , Katakam Sudhakar Babu , Parashuram Shivashankar , Jayaprakash Vijayvel , Pillai M. Radhakrishna
Published: April 2023

Abstract
Oral leukoplakia is a potentially malignant lesion of the oral cavity, for which no effective treatment is available. We investigated the effectiveness of curcumin, a potent inhibitor of NF-κB/COX-2, molecules perturbed in oral carcinogenesis, to treat leukoplakia. Subjects with oral leukoplakia (n = 223) were randomized (1:1 ratio) to receive orally, either 3.6 g/day of curcumin (n = 111) or placebo (n = 112), for 6 months. The primary endpoint was clinical response obtained by bi-dimensional measurement of leukoplakia size at recruitment and 6 months. Histologic response, combined clinical and histologic response, durability and effect of long-term therapy for an additional six months in partial responders, safety and compliance were the secondary endpoints. Clinical response was observed in 75 (67.5%) subjects [95% confidence interval (CI), 58.4–75.6] in the curcumin and 62 (55.3%; 95% CI, 46.1–64.2) in placebo arm (P = 0.03). This response was durable, with 16 of the 18 (88.9%; 95% CI, 67.2–96.9) subjects with complete response in curcumin and 7 of 8 subjects (87.5%) in placebo arm, demonstrating no relapse after 6 months follow-up. Difference in histologic response between curcumin and placebo was not significant (HR, 0.88, 95% CI, 0.45–1.71; P = 0.71). Combined clinical and histologic response assessment indicated a significantly better response with curcumin (HR, 0.50; 95% CI, 0.27–0.92; P = 0.02). Continued therapy, in subjects with partial response at 6 months, did not yield additional benefit. The treatment did not raise any safety concerns. Treatment of oral leukoplakia with curcumin (3.6 g for six months), thus was well tolerated and demonstrated significant and durable clinical response for 6 months. Cancer Prev Res; 9(8); 683–91. ©2016 AACR.
Data from The Acceptability and Preference of Vaginal Self-sampling for Human Papillomavirus (HPV) Testing among a Multi-ethnic Asian Female Population
Authors: Khoo Su Pei , Lim Wen Tzien , Rajasuriar Reena , Nasir Nazrila Hairizan , Gravitt Patti , Woo Yin Ling
Published: April 2023

Abstract
Vaginal self-sampling for human papillomavirus (HPV) testing can potentially increase cervical screening coverage. This study aimed to investigate the acceptability of vaginal self-sampling for HPV testing and factors that might influence a woman's preference for this as a cervical screening method. This was a cross-sectional study that recruited 725 women from the urban and suburban areas of Selangor, Malaysia. All study participants were instructed to self-collect vaginal sample using a dry flocked swab before responding to a detailed questionnaire documenting their experience and preference for self-sampling. Most of the study participants (>80%) perceived vaginal self-sampling as easy, convenient, not embarrassing, comfortable, and were confident in performing the test. This suggests high acceptability toward vaginal self-sampling for HPV testing. Of the 725 women, 83% preferred self-sampling HPV testing over healthcare personnel sampling HPV testing and Pap test. Women with higher household income and full-time employment status were more likely to prefer self-sampling. Those who had not undergone Pap test also expressed preference for self-sampling HPV testing. Convenience and women's confidence in performing a vaginal self-sampling for HPV testing were the independent key factors that influenced the preference for self-sampling method. Vaginal self-sampling for HPV testing is highly acceptable among Malaysian women. It is the preferred choice as a primary cervical screening method and serves as an alternative to healthcare-acquired sample for Pap test.
Prevention Relevance:
Organized cervical cancer screening remains unachievable in many countries. Self-sampling HPV testing is an evidence-based method that can remove barriers to cervical screening. This is particularly important for developing countries in order to achieve the WHO global strategy to accelerate cervical cancer elimination.
Data from Simple Prediction Model for Colorectal Serrated Polyps: Development and External Validation Study in U.S. Prospective Cohorts
Authors: Lyu Zhangyan , Hang Dong , He Xiaosheng , Wu Kana , Cao Yin , Rosner Bernard , Chan Andrew T. , Ogino Shuji , Li Ni , Dai Min , Giovannucci Edward L. , Song Mingyang
Published: April 2023

Abstract
Serrated polyps (SP) are precursors for colorectal cancer and contribute disproportionately to postcolonoscopy cancers. Leveraging three U.S. cohorts (43,974 women and 5,322 men), we developed prediction models for high-risk SPs (sized ≥10 mm or ≥3) among individuals undergoing their first colonoscopy screening. We then validated the model in the Partners Colonoscopy Cohort (51,203 women and 39,077 men). We evaluated discrimination and calibration using the C-statistic and Hosmer–Lemeshow test, respectively. The age and family history model generated a C-statistic [95% confidence interval (CI)] of 0.57 (0.56–0.58) in women and 0.58 (0.55–0.61) in men. Further inclusion of smoking, alcohol, and body mass index (the simple model) increased the C-statistic (95% CI) to 0.68 (0.67–0.69) in women and 0.68 (0.66–0.71) in men (all P < 0.001). Adding more predictors did not provide much incremental predictivity. In the validation cohort, moderate discrimination was observed in both women (0.60, 0.58–0.61) and men (0.60, 0.59–0.62). Notably, the simple model also yielded similar C-statistics for a composite endpoint of SPs and high-risk conventional adenomas (women, 0.62, 0.62–0.63; men, 0.63, 0.61–0.64). The model was adequately calibrated in both sets of cohorts. In summary, we developed and externally validated a simple prediction model based on five major risk factors for high-risk SPs that may be useful for healthy lifestyle recommendations and tailored colorectal cancer screening.
Prevention Relevance:
On the basis of four prospective studies in the United States, we developed and externally validated a simple risk prediction model for high-risk SPs in the setting of colonoscopy screening. Our model showed moderate discriminatory accuracy and has potential utility for individualized risk assessment, healthy lifestyle recommendations, and tailored colorectal cancer prevention.
Supplementary Table S2 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
Authors: Andraos Rita , Qian Zhiyan , Bonenfant Débora , Rubert Joëlle , Vangrevelinghe Eric , Scheufler Clemens , Marque Fanny , Régnier Catherine H. , De Pover Alain , Ryckelynck Hugues , Bhagwat Neha , Koppikar Priya , Goel Aviva , Wyder Lorenza , Tavares Gisele , Baffert Fabienne , Pissot-Soldermann Carole , Manley Paul W. , Gaul Christoph , Voshol Hans , Levine Ross L. , Sellers William R. , Hofmann Francesco , Radimerski Thomas
Published: April 2023

PDF file - 111K, Overview of phosphopeptides detected by mass-spectrometry following treatment of SET-2 cells with different JAK inhibitors. Changes in phosphopeptide abundance following JAK inhibitor treatment versus DMSO vehicle control treatment in the different experiments are displayed as log2 ratios calculated from duplicate runs. No value = not detected.
Supplementary Figure 2 from Evolutionary Pathways in BRCA1-Associated Breast Tumors
Authors: Martins Filipe C. , De Subhajyoti , Almendro Vanessa , Gönen Mithat , Park So Yeon , Blum Joanne L. , Herlihy William , Ethington Gabrielle , Schnitt Stuart J. , Tung Nadine , Garber Judy E. , Fetten Katharina , Michor Franziska , Polyak Kornelia
Published: April 2023

PDF file - 149K, Evolutionary paths and BRCA1 expression in breast tumors.
Supplementary Figure S5 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
Authors: Jahchan Nadine S. , Dudley Joel T. , Mazur Pawel K. , Flores Natasha , Yang Dian , Palmerton Alec , Zmoos Anne-Flore , Vaka Dedeepya , Tran Kim Q.T. , Zhou Margaret , Krasinska Karolina , Riess Jonathan W. , Neal Joel W. , Khatri Purvesh , Park Kwon S. , Butte Atul J. , Sage Julien
Published: April 2023

- PDF file 779K, Induction of cell death in SCLC cells after treatment with related TCAs and with specific GPCR inhibitors
Video 1 from DEAR1 Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-β–Driven Epithelial–Mesenchymal Transition
Authors: Chen Nanyue , Balasenthil Seetharaman , Reuther Jacquelyn , Frayna Aileen , Wang Ying , Chandler Dawn S. , Abruzzo Lynne V. , Rashid Asif , Rodriguez Jaime , Lozano Guillermina , Cao Yu , Lokken Erica , Chen Jinyun , Frazier Marsha L. , Sahin Aysegul A. , Wistuba Ignacio I. , Sen Subrata , Lott Steven T. , Killary Ann McNeill
Published: April 2023

Video 1 - MP4 file 3450K, Control shRNA clone without TGF-beta
Supplementary Materials from DEAR1 Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-β–Driven Epithelial–Mesenchymal Transition
Authors: Chen Nanyue , Balasenthil Seetharaman , Reuther Jacquelyn , Frayna Aileen , Wang Ying , Chandler Dawn S. , Abruzzo Lynne V. , Rashid Asif , Rodriguez Jaime , Lozano Guillermina , Cao Yu , Lokken Erica , Chen Jinyun , Frazier Marsha L. , Sahin Aysegul A. , Wistuba Ignacio I. , Sen Subrata , Lott Steven T. , Killary Ann McNeill
Published: April 2023

Supplementary Materials - PDF file 3317K, Including supplementary methods, supplementary figures and legends, and supplementary tables
Supplementary Tables 1-2 from Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Authors: Jaspers Janneke E. , Kersbergen Ariena , Boon Ute , Sol Wendy , van Deemter Liesbeth , Zander Serge A. , Drost Rinske , Wientjens Ellen , Ji Jiuping , Aly Amal , Doroshow James H. , Cranston Aaron , Martin Niall M.B. , Lau Alan , O'Connor Mark J. , Ganesan Shridar , Borst Piet , Jonkers Jos , Rottenberg Sven
Published: April 2023

PDF file - 28K, Information on all antibodies and primers that were used in this study
Supplementary Figure Legends 1-5 from HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Authors: Takezawa Ken , Pirazzoli Valentina , Arcila Maria E. , Nebhan Caroline A. , Song Xiaoling , de Stanchina Elisa , Ohashi Kadoaki , Janjigian Yelena Y. , Spitzler Paula J. , Melnick Mary Ann , Riely Greg J. , Kris Mark G. , Miller Vincent A. , Ladanyi Marc , Politi Katerina , Pao William
Published: April 2023

PDF file - 29K
Supplementary Table S4 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Authors: Girotti Maria R. , Pedersen Malin , Sanchez-Laorden Berta , Viros Amaya , Turajlic Samra , Niculescu-Duvaz Dan , Zambon Alfonso , Sinclair John , Hayes Andrew , Gore Martin , Lorigan Paul , Springer Caroline , Larkin James , Jorgensen Claus , Marais Richard
Published: April 2023

PDF file - 60K, Proteins with differentially regulated phosphopeptides corresponding to the cytoskeleton group according to DAVID GO analysis
Interview with Dr. Mischel from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
Authors: Tanaka Kazuhiro , Babic Ivan , Nathanson David , Akhavan David , Guo Deliang , Gini Beatrice , Dang Julie , Zhu Shaojun , Yang Huijun , De Jesus Jason , Amzajerdi Ali Nael , Zhang Yinan , Dibble Christian C. , Dan Hancai , Rinkenbaugh Amanda , Yong William H. , Vinters Harry V. , Gera Joseph F. , Cavenee Webster K. , Cloughesy Timothy F. , Manning Brendan D. , Baldwin Albert S. , Mischel Paul S.
Published: April 2023

mp3 file (9.8 MB). In the November edition of the Cancer Discovery podcast, Executive Editor Mark Landis talks with Paul S. Mischel about his paper, which identifies mTORC2 as a novel mediator of drug resistance and regulator of NF-κB signaling in glioblastoma.
Supplementary Material from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Authors: Girotti Maria R. , Pedersen Malin , Sanchez-Laorden Berta , Viros Amaya , Turajlic Samra , Niculescu-Duvaz Dan , Zambon Alfonso , Sinclair John , Hayes Andrew , Gore Martin , Lorigan Paul , Springer Caroline , Larkin James , Jorgensen Claus , Marais Richard
Published: April 2023

PDF file - 124K, Contains extended Materials and Methods for the manuscript
Supplementary Figure 4 from A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Authors: Whittaker Steven R. , Theurillat Jean-Philippe , Van Allen Eliezer , Wagle Nikhil , Hsiao Jessica , Cowley Glenn S. , Schadendorf Dirk , Root David E. , Garraway Levi A.
Published: April 2023

Supplementary Figure 4 PDF file - 38K, Identification of human melanoma and colorectal cancer cell lines with coincident B-RAF and NF1 mutations is associated with resistance to PLX4720. Human melanoma and colorectal cancer cell lines from the Cancer Cell Line Encyclopedia with B-RAFV600E and NF1 mutation were identified and compared to NF1 wild-type melanoma cell lines in terms of sensitivity to PLX4720, NF1 mRNA expression, NF1 copy number alterations and NF1 mutation status. In the heat map, blue represents lower values and red represents higher values, whilst NF1 mutation status is represented as wild-type: blue, point mutation: white, potential loss-of-function mutation: red
Supplementary Figure 1 from A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Authors: Whittaker Steven R. , Theurillat Jean-Philippe , Van Allen Eliezer , Wagle Nikhil , Hsiao Jessica , Cowley Glenn S. , Schadendorf Dirk , Root David E. , Garraway Levi A.
Published: April 2023

Supplementary Figure 1 PDF file - 375K, Primary melanocytes expressing oncogenic B-RAF are rendered resistant to PLX4720 following NF1 knockdown. (A) Immortalized human primary melanocytes expressing Myc-tagged B-RAFV600E were infected with shRNAs against NF1 and a control, non-targeting shRNA. Cells were treated with a 9-point concentration response of PLX4720 for 7 d and cell proliferation assessed by cell-titer glo assay. (B) Primary melanocytes from (A) were seeded at low density and exposed to 3 �M PLX4720. Colony formation was determined after 10 d in culture by staining with crystal violet. (C) Primary melanocytes infected with the indicated shRNAs were treated with 0.2 or 1 �M PLX4720 for 16 h. Cell lysates were analyzed for the indicated proteins.
Supplementary Figures 1-9 from Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers
Authors: Cheung Hiu Wing , Du Jinyan , Boehm Jesse S. , He Frank , Weir Barbara A. , Wang Xiaoxing , Butaney Mohit , Sequist Lecia V. , Luo Biao , Engelman Jeffrey A. , Root David E. , Meyerson Matthew , Golub Todd R. , Jänne Pasi A. , Hahn William C.
Published: April 2023

PDF file - 1.5MB
Supplementary Data from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
Authors: Serra Violeta , Vivancos Ana , Puente Xose S. , Felip Enriqueta , Silberschmidt Daniel , Caratù Ginevra , Parra Josep-Lluís , De Mattos-Arruda Leticia , Grueso Judit , Hernández-Losa Javier , Arribas Joaquín , Prudkin Ludmila , Nuciforo Paolo , Scaltriti Maurizio , Seoane Joan , Baselga José
Published: April 2023

Supplementary Data - PDF file 124K, Methods, Supplementary Figure Legends, Supplementary Table Legend
Supplementary Figure Legends 1-6, Table Legend 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Authors: Ibrahim Yasir H. , García-García Celina , Serra Violeta , He Lei , Torres-Lockhart Kristine , Prat Aleix , Anton Pilar , Cozar Patricia , Guzmán Marta , Grueso Judit , Rodríguez Olga , Calvo Maria Teresa , Aura Claudia , Díez Orland , Rubio Isabel T. , Pérez José , Rodón Jordi , Cortés Javier , Ellisen Leif W. , Scaltriti Maurizio , Baselga José
Published: April 2023

PDF file - 58K
Supplementary Methods from Cancer-Specific Requirement for BUB1B/BUBR1 in Human Brain Tumor Isolates and Genetically Transformed Cells
Authors: Ding Yu , Hubert Christopher G. , Herman Jacob , Corrin Philip , Toledo Chad M. , Skutt-Kakaria Kyobi , Vazquez Julio , Basom Ryan , Zhang Bin , Risler Jennifer K. , Pollard Steven M. , Nam Do-Hyun , Delrow Jeffery J. , Zhu Jun , Lee Jeongwu , DeLuca Jennifer , Olson James M. , Paddison Patrick J.
Published: April 2023

PDF file - 117K
Supplementary Table 3 from Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Authors: Beltran Himisha , Rickman David S. , Park Kyung , Chae Sung Suk , Sboner Andrea , MacDonald Theresa Y. , Wang Yuwei , Sheikh Karen L. , Terry Stéphane , Tagawa Scott T. , Dhir Rajiv , Nelson Joel B. , de la Taille Alexandre , Allory Yves , Gerstein Mark B. , Perner Sven , Pienta Kenneth J. , Chinnaiyan Arul M. , Wang Yuzhuo , Collins Colin C. , Gleave Martin E. , Demichelis Francesca , Nanus David M. , Rubin Mark A.
Published: April 2023

PDF file - 635K
Supplementary Figure legends from Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS-Mutant Lung Cancer
Authors: Molina-Arcas Miriam , Hancock David C. , Sheridan Clare , Kumar Madhu S. , Downward Julian
Published: April 2023

Supplementary Figure legends - PDF file 84K, Supplementary Figure legends 1-10
Supplementary Figures 1-12 from Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Authors: Ercan Dalia , Xu Chunxiao , Yanagita Masahiko , Monast Calixte S. , Pratilas Christine A. , Montero Joan , Butaney Mohit , Shimamura Takeshi , Sholl Lynette , Ivanova Elena V. , Tadi Madhavi , Rogers Andrew , Repellin Claire , Capelletti Marzia , Maertens Ophélia , Goetz Eva M. , Letai Anthony , Garraway Levi A. , Lazzara Matthew J. , Rosen Neal , Gray Nathanael S. , Wong Kwok-Kin , Jänne Pasi A.
Published: April 2023

PDF file - 1.3MB, Supplementary data on MAPK1 copy number and expression, combination treatment with WZ4002 and PI3K inhibitors, impact of MEK1 K57N on WZ4002 sensitivity, Mapk1 copy number analyses and NF1 and dusp expression in drug sensitive and resistant mouse tumors
Supplementary Figure 8 from Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS-Mutant Lung Cancer
Authors: Molina-Arcas Miriam , Hancock David C. , Sheridan Clare , Kumar Madhu S. , Downward Julian
Published: April 2023

Supplementary Figure 8 - PDF file 459K, Indicators of IGF1R pathway activity in NSCLC cell lines
Supplementary Table 4 from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Authors: Geng Huimin , Brennan Sarah , Milne Thomas A. , Chen Wei-Yi , Li Yushan , Hurtz Christian , Kweon Soo-Mi , Zickl Lynette , Shojaee Seyedmehdi , Neuberg Donna , Huang Chuanxin , Biswas Debabrata , Xin Yuan , Racevskis Janis , Ketterling Rhett P. , Luger Selina M. , Lazarus Hillard , Tallman Martin S. , Rowe Jacob M. , Litzow Mark R. , Guzman Monica L. , Allis C. David , Roeder Robert G. , Müschen Markus , Paietta Elisabeth , Elemento Olivier , Melnick Ari M.
Published: April 2023

XLS file - 330K, Genes included in BCR-ABL1, E2A-PBX1 or MLLr DNA methylation signatures vs. normal pre-B cells
Press Conference from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
Authors: Ulmert David , Evans Michael J. , Holland Jason P. , Rice Samuel L. , Wongvipat John , Pettersson Kim , Abrahamsson Per-Anders , Scardino Peter T. , Larson Steven M. , Lilja Hans , Lewis Jason S. , Sawyers Charles L.
Published: April 2023

mp3 file (37.5 MB). "Personalized Medicine: Late-breaking Science from AACR Journals," Saturday, March 31, 2012. Hosted by Lewis C. Cantley, Co-Editor-in-Chief of Cancer Discovery, this press conference held during the AACR Annual Meeting covers the following topics:

Lack of Oxygen Influenced Tumor Behavior and Patient Outcome in Intermediate-risk Prostate Cancer

Novel Technology Allows for Noninvasive Imaging of Prostate Cancer (Ulmert et al., April issue of Cancer Discovery)

EGFR Mutation Unique to Glioblastoma May Explain Lack of Response to Traditional EGFR Inhibitors
Supplementary Methods and Data (posted 7/5/2011) from Characterization of KRAS Rearrangements in Metastatic Prostate Cancer
Authors: Wang Xiao-Song , Shankar Sunita , Dhanasekaran Saravana M. , Ateeq Bushra , Sasaki Atsuo T. , Jing Xiaojun , Robinson Daniel , Cao Qi , Prensner John R. , Yocum Anastasia K. , Wang Rui , Fries Daniel F. , Han Bo , Asangani Irfan A. , Cao Xuhong , Li Yong , Omenn Gilbert S. , Pflueger Dorothee , Gopalan Anuradha , Reuter Victor E. , Kahoud Emily Rose , Cantley Lewis C. , Rubin Mark A. , Palanisamy Nallasivam , Varambally Sooryanarayana , Chinnaiyan Arul M.
Published: April 2023

Supplementary Methods and Data (posted 7/5/2011) from Characterization of KRAS Rearrangements in Metastatic Prostate Cancer
Supplementary Movie 1 from Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium
Authors: Iwanicki Marcin P. , Davidowitz Rachel A. , Ng Mei Rosa , Besser Achim , Muranen Taru , Merritt Melissa , Danuser Gaudenz , Ince Tan , Brugge Joan S.
Published: April 2023

File Type: .mov; File Size: 1 MB.
Supplementary Table 5 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
Authors: Sanda Takaomi , Tyner Jeffrey W. , Gutierrez Alejandro , Ngo Vu N. , Glover Jason , Chang Bill H. , Yost Arla , Ma Wenxue , Fleischman Angela G. , Zhou Wenjun , Yang Yandan , Kleppe Maria , Ahn Yebin , Tatarek Jessica , Kelliher Michelle A. , Neuberg Donna S. , Levine Ross L. , Moriggl Richard , Müller Mathias , Gray Nathanael S. , Jamieson Catriona H.M. , Weng Andrew P. , Staudt Louis M. , Druker Brian J. , Look A. Thomas
Published: April 2023

XLSX file - 14291K, TYK2 genotype in 17 T-ALL cell lines.
Supplementary Movie 3 from The Outgrowth of Micrometastases Is Enabled by the Formation of Filopodium-like Protrusions
Authors: Shibue Tsukasa , Brooks Mary W. , Inan M. Fatih , Reinhardt Ferenc , Weinberg Robert A.
Published: April 2023

MOV file - 3.4MB, Direct conversion of FLP-associated integrin clumps into the ones constituting adhesion plaques
Supplementary Movie 2 from The Outgrowth of Micrometastases Is Enabled by the Formation of Filopodium-like Protrusions
Authors: Shibue Tsukasa , Brooks Mary W. , Inan M. Fatih , Reinhardt Ferenc , Weinberg Robert A.
Published: April 2023

MOV file - 3.4MB, Kinetics of the assembly and disassembly of FLPs in cells cultured under MoT conditions
Supplementary Movie 1 from The Outgrowth of Micrometastases Is Enabled by the Formation of Filopodium-like Protrusions
Authors: Shibue Tsukasa , Brooks Mary W. , Inan M. Fatih , Reinhardt Ferenc , Weinberg Robert A.
Published: April 2023

MOV file - 3.4MB, Kinetics of the assembly and disassembly of filopodia in cells cultured under monolayer conditions
Supplementary Figure 6 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
Authors: Sanda Takaomi , Tyner Jeffrey W. , Gutierrez Alejandro , Ngo Vu N. , Glover Jason , Chang Bill H. , Yost Arla , Ma Wenxue , Fleischman Angela G. , Zhou Wenjun , Yang Yandan , Kleppe Maria , Ahn Yebin , Tatarek Jessica , Kelliher Michelle A. , Neuberg Donna S. , Levine Ross L. , Moriggl Richard , Müller Mathias , Gray Nathanael S. , Jamieson Catriona H.M. , Weng Andrew P. , Staudt Louis M. , Druker Brian J. , Look A. Thomas
Published: April 2023

PDF file - 32K, Expressions of IL-10 and IL-10 receptors, and effect of an anti-IL10 neutralizing antibody on growth of T-ALL cell lines.
Supplementary Figures 1-10 from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
Authors: Vivanco Igor , Robins H. Ian , Rohle Daniel , Campos Carl , Grommes Christian , Nghiemphu Phioanh Leia , Kubek Sara , Oldrini Barbara , Chheda Milan G. , Yannuzzi Nicolas , Tao Hui , Zhu Shaojun , Iwanami Akio , Kuga Daisuke , Dang Julie , Pedraza Alicia , Brennan Cameron W. , Heguy Adriana , Liau Linda M. , Lieberman Frank , Yung W. K. Alfred , Gilbert Mark R. , Reardon David A. , Drappatz Jan , Wen Patrick Y. , Lamborn Kathleen R. , Chang Susan M. , Prados Michael D. , Fine Howard A. , Horvath Steve , Wu Nian , Lassman Andrew B. , DeAngelis Lisa M. , Yong William H. , Kuhn John G. , Mischel Paul S. , Mehta Minesh P. , Cloughesy Timothy F. , Mellinghoff Ingo K.
Published: April 2023

PDF file - 689K
Supplementary Figure 1 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
Authors: Sanda Takaomi , Tyner Jeffrey W. , Gutierrez Alejandro , Ngo Vu N. , Glover Jason , Chang Bill H. , Yost Arla , Ma Wenxue , Fleischman Angela G. , Zhou Wenjun , Yang Yandan , Kleppe Maria , Ahn Yebin , Tatarek Jessica , Kelliher Michelle A. , Neuberg Donna S. , Levine Ross L. , Moriggl Richard , Müller Mathias , Gray Nathanael S. , Jamieson Catriona H.M. , Weng Andrew P. , Staudt Louis M. , Druker Brian J. , Look A. Thomas
Published: April 2023

PDF file - 61K, Validation of shRNA constructs.
Supplementary Figures 1 - 4 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
Authors: Braas Daniel , Ahler Ethan , Tam Brenna , Nathanson David , Riedinger Mirielle , Benz Matthias R. , Smith Kathleen B. , Eilber Fritz C. , Witte Owen N. , Tap William D. , Wu Hong , Christofk Heather R.
Published: April 2023

PDF file - 163K, Supplemental Figure 1: Serially passaged liposarcoma xenograft tumors derived from primary tumors and xenograft tumors derived from liposarcoma cell lines both exhibit similar 18F-FDG uptake by PET. Supplemental Figure 2: High grade liposarcomas exhibit variable FDG uptake by PET. Supplemental Figure 3: Nutrient concentrations in medium and metabolites consumed by liposarcoma cell lines. Supplemental Figure 4: Glucose and glutamine consumption rates and lactate production rates are similar in three liposarcoma cell lines.
Supplementary Tables 1-11 from Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
Authors: Herrero Rolando , Wacholder Sholom , Rodríguez Ana C. , Solomon Diane , González Paula , Kreimer Aimee R. , Porras Carolina , Schussler John , Jiménez Silvia , Sherman Mark E. , Quint Wim , Schiller John T. , Lowy Douglas R. , Schiffman Mark , Hildesheim Allan
Published: April 2023

PDF file - 347K
Supplementary Table 2 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
Authors: Hyman David M. , Diamond Eli L. , Vibat Cecile Rose T. , Hassaine Latifa , Poole Jason C. , Patel Minal , Holley Veronica R. , Cabrilo Goran , Lu Timothy T. , Arcila Maria E. , Chung Young Rock , Rampal Raajit , Lacouture Mario E. , Rosen Neal , Meric-Bernstam Funda , Baselga José , Kurzrock Razelle , Erlander Mark G. , Janku Filip , Abdel-Wahab Omar
Published: April 2023

Supplemental Table 2: Concordance of initial plasma cell-free DNA (cfDNA) assessment of BRAFV600E mutations with tissue biopsy BRAFV600E result.
Supplementary File Legends from Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Authors: Brastianos Priscilla K. , Carter Scott L. , Santagata Sandro , Cahill Daniel P. , Taylor-Weiner Amaro , Jones Robert T. , Van Allen Eliezer M. , Lawrence Michael S. , Horowitz Peleg M. , Cibulskis Kristian , Ligon Keith L. , Tabernero Josep , Seoane Joan , Martinez-Saez Elena , Curry William T. , Dunn Ian F. , Paek Sun Ha , Park Sung-Hye , McKenna Aaron , Chevalier Aaron , Rosenberg Mara , Barker Frederick G. , Gill Corey M. , Van Hummelen Paul , Thorner Aaron R. , Johnson Bruce E. , Hoang Mai P. , Choueiri Toni K. , Signoretti Sabina , Sougnez Carrie , Rabin Michael S. , Lin Nancy U. , Winer Eric P. , Stemmer-Rachamimov Anat , Meyerson Matthew , Garraway Levi , Gabriel Stacey , Lander Eric S. , Beroukhim Rameen , Batchelor Tracy T. , Baselga José , Louis David N. , Getz Gad , Hahn William C.
Published: April 2023

Supplementary File Legends
Supplementary Table S1 - S3 from Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma
Authors: Ryan Russell J.H. , Drier Yotam , Whitton Holly , Cotton M. Joel , Kaur Jasleen , Issner Robbyn , Gillespie Shawn , Epstein Charles B. , Nardi Valentina , Sohani Aliyah R. , Hochberg Ephraim P. , Bernstein Bradley E.
Published: April 2023

Supplementary Table S1. Clinical and diagnostic information on lymphoma cases. Supplementary Table S2. Rearrangements detected by PEAR-ChIP in 14 lymphoma primary samples and 8 lymphoma cell lines. Supplementary Table S3. Detection of large-scale rearrangements at known oncogene loci in four HGB lymphoma cell lines by whole genome sequencing data, in comparison to PEARChIP.
Supplementary Figure S4 from Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma
Authors: Ryan Russell J.H. , Drier Yotam , Whitton Holly , Cotton M. Joel , Kaur Jasleen , Issner Robbyn , Gillespie Shawn , Epstein Charles B. , Nardi Valentina , Sohani Aliyah R. , Hochberg Ephraim P. , Bernstein Bradley E.
Published: April 2023

Supplementary Figure S4. Genome-wide correlation and motif analysis of MEF2B and p300 ChIP-Seq in HGB cell lines.
Supplementary Figure 7 from Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution
Authors: Dewhurst Sally M. , McGranahan Nicholas , Burrell Rebecca A. , Rowan Andrew J. , Grönroos Eva , Endesfelder David , Joshi Tejal , Mouradov Dmitri , Gibbs Peter , Ward Robyn L. , Hawkins Nicholas J. , Szallasi Zoltan , Sieber Oliver M. , Swanton Charles
Published: April 2023

PDF file 1328K, Supplementary Figure 7: Correlation of copy number losses and gains across whole genome with increasing wGII in TCGA CRC tumours
Supplementary Table 1 from A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors
Authors: Van Rechem Capucine , Black Joshua C. , Greninger Patricia , Zhao Yang , Donado Carlos , Burrowes Paul d. , Ladd Brendon , Christiani David C. , Benes Cyril H. , Whetstine Johnathan R.
Published: April 2023

Supplementary Table 1. KDM4A SNP-A482 associates with cellular sensitivity to drugs targeting the mTOR pathway.
Supplementary Figure S3 from Unbiased Metabolite Profiling Indicates That a Diminished Thymidine Pool Is the Underlying Mechanism of Colon Cancer Chemoprevention by Alpha-Difluoromethylornithine
Authors: Witherspoon Mavee , Chen Qiuying , Kopelovich Levy , Gross Steven S. , Lipkin Steven M.
Published: April 2023

Supplementary Figure S3 - PDF file 234K, Fig.S3. Untargeted Metabolite Profiling of DFMO Treated ApcMin Mouse Tumors. Metabolite profiling identified differentially-expressed metabolites in DFMO-treated ApcMin mouse tumors, compared to tumors from untreated ApcMin mice (P<0.05). Panel A: 1,165 aligned features were detected in all replicates from at least one treatment group by untargeted molecular feature extraction (n = 4/group). Panel B: Principal component analysis score plot of all 1,165 features detected in all replicates of at least one group. Notably, the first three components account for 73.5% of the total variances in the data. The DFMO treated group clustered and separated from untreated controls along the PC1-axis, which constituted 50.5% of total variance. Panel C: Unsupervised hierarchical clustering analysis dendrogram, listing differentially expressed metabolites in tumors from DFMO treated vs. untreated mice. The relative level of expression of each metabolite is represented by a color-coded heat map, where red represents the highest expression and blue represents the lowest expression compared to mean values. Panel D: Volcano plot analysis, showing that levels of 327 features were altered in expression by 2.0-fold or greater after DFMO treatment (*p < 0.05)
Supplementary Figure Legends from Unbiased Metabolite Profiling Indicates That a Diminished Thymidine Pool Is the Underlying Mechanism of Colon Cancer Chemoprevention by Alpha-Difluoromethylornithine
Authors: Witherspoon Mavee , Chen Qiuying , Kopelovich Levy , Gross Steven S. , Lipkin Steven M.
Published: April 2023

Supplementary Figure Legends - PDF file 30K, Supplementary Figure Legends
Supplementary Figure 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Authors: Walter Annette O. , Sjin Robert Tjin Tham , Haringsma Henry J. , Ohashi Kadoaki , Sun Jing , Lee Kwangho , Dubrovskiy Aleksandr , Labenski Matthew , Zhu Zhendong , Wang Zhigang , Sheets Michael , St Martin Thia , Karp Russell , van Kalken Dan , Chaturvedi Prasoon , Niu Deqiang , Nacht Mariana , Petter Russell C. , Westlin William , Lin Kevin , Jaw-Tsai Sarah , Raponi Mitch , Van Dyke Terry , Etter Jeff , Weaver Zoe , Pao William , Singh Juswinder , Simmons Andrew D. , Harding Thomas C. , Allen Andrew
Published: April 2023

Supplementary Figure 1 - PDF file 596K, Covalent binding of the EGFR L858R/T790M protein by CO-1686